^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

    Excerpt:
    ...- Patients must have esophageal, gastric or gastroesophageal adenocarcinoma with HER2 overexpression and/or amplification as determined by next generation sequencing assay, immunohistochemistry (IHC 3+) or fluorescent in situ hybridization (FISH+ is defined as HER2:CEP17 ratio ≥ 2.0)....
    Trial ID:
    NCT02954536
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2021
    Title:

    A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.

    Published date:
    01/11/2021
    Excerpt:
    First-line triplet regimen (Pembrolizumab, Trastuzumab, and Chemotherapy) showed promising efficacy based on HER2 amplification by NGS regardless of PD-L1 status in AGC/GEJ cancer.
    Secondary therapy:
    cisplatin + capecitabine
    DOI:
    10.1200/JCO.2021.39.3_suppl.218
    Trial ID:
    NCT02901301